Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
26 results
D2.02 - Clinically Relevant Cross-Reactivity Between Artemisia vulgaris and Bee Pollen: A New Paradigm in Postprandial Exercise-Induced Anaphylaxis
D2.04 - PREVALENCE OF ALPHA-GAL SENSITIZATION IN PATIENTS WITH ARTHROPOD BITE REACTIONS, CHRONIC SPONTANEOUS URTICARIA AND GASTROINTESTINAL SYMPTOMS IN LA RIOJA (SPAIN). Introduction
D2.07 - Cross-reactivity of Major Pollen Allergens in Spring in Beijing
D2.08 - Extraction Efficiency Studies and Quantification of Major Peanut Allergens in Peanut Challenge Meals and Peanut Flour
D2.09 - Qualitative concordance between two multiplex molecular diagnostic platforms in LTP allergy
D2.10 - Early-onset cow’s milk protein and tree nut allergy: the value of component-resolved diagnosis in interpreting low-level alpha-gal sensitization
D2.12 - Resolving heterophile antibody interference in the ISAC multiplex assay using HBT (Scantibodies)
D2.13 - Migratory locust and house cricket as food allergy: cross reactivity or primary sensitivisation
D2.14 - Component ratio analysis supports a targeted diagnostic approach in house dust mite allergy
D2.03 - Cofactor-Dependent Anaphylaxis to Rosaceae and Citrus Fruits: Molecular Characterization Reveals High-Molecular-Weight Allergens Beyond Classical Panallergens
D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies
D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection
D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper
D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use
D2.455 - Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD
D2.456 - Chronic sinusitis with nasal polyposis: Add-on aspirin desensitization useful in dupilumab therapy?
D2.461 - Endothelial related miRs are dysregulated in C1-INH Angioedema patients: new potential biomarkers and therapeutic targets
D2.462 - Safety and predictors of tolerance in rituximab hypersensitivity management
D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial
D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download